Osteoporosis drugs linked to lower dementia risk in older adults

• Taking nitrogen-containing bisphosphonates was associated with a 16% lower risk of dementia than taking no osteoporosis medication.
• Compared with other osteoporosis medications, people taking bisphosphonates had a 24% lower risk.
• The observational study does not prove that the medications directly prevent dementia.

What exactly the study found

Researchers at the University of Hong Kong Faculty of Medicine found an association between taking certain osteoporosis medications and a lower likelihood of dementia. These are nitrogen-containing bisphosphonates, or NBPs, which include commonly prescribed bone-strengthening drugs. The study was based on data from more than 120,000 patients aged 60 and older. The findings were published in the journal Alzheimer’s & Dementia, but do not in themselves confirm that the medications prevent the disease.

Compared with patients who had not received osteoporosis medication, those taking NBP had a 16% lower risk of Alzheimer’s disease and related dementias. Compared with people prescribed other types of osteoporosis medication, the difference was 24% in favor of the NBP group. These are relative figures reported by the study authors; they describe an association between treatment and outcomes in the data studied, not a guaranteed reduction in risk for every patient.

The association was stronger among women and patients who had experienced a hip fracture. The authors also calculated that treating 48 patients with bisphosphonates for five years could potentially prevent one case of dementia. This estimate reflects the results of the analysis and should not be understood as a confirmed treatment effect: the study was observational. The researchers emphasize the need for further investigation into whether the medications truly affect the likelihood of cognitive decline.

Why bone-strengthening drugs were studied

Nitrogen-containing bisphosphonates are used to treat osteoporosis, a condition in which bones become weaker and break more easily. These drugs, including alendronate and zoledronate, slow the breakdown of bone tissue, helping preserve its strength and reduce the likelihood of fractures. Their possible effects on the brain are being studied separately: researchers became interested because some biological processes targeted by these drugs may also be linked to the development of Alzheimer’s disease and other dementias.

Osteoporosis and dementia often affect the same older people. The study report listed older age, female sex, and low physical activity among the shared risk factors. The relationship may also work both ways: an earlier study by the same team identified osteoporosis and fractures as independent risk factors for dementia, while people who already had dementia were found to be more likely to fall and fracture bones. This provided a basis for examining a possible link between bone treatment and dementia risk.

Interest in this question is also driven by the need for ways to prevent or delay dementia. According to figures cited by the authors, more than 55 million people worldwide live with the condition, and that number could reach 139 million by 2050. New drugs designed to slow Alzheimer’s disease and related dementias have already been approved, but their cost, their suitability for only some patients, and questions about their effectiveness remain challenges. That is why scientists are studying drugs already in use and their possible additional effects.

How the patients were compared

The HKUMed team analysed electronic medical records from across Hong Kong. The sample included more than 120,000 patients aged 60 or older who had osteoporosis or so-called fragility fractures—injuries that can occur after relatively minor trauma because of weakened bones. The makeup of the sample is important for interpreting the findings: the study concerns people with bone problems, not all older residents or the population as a whole.

Medical records covered the period from 2005 to 2020. This allowed researchers to compare prescribed osteoporosis treatments with subsequent cases of dementia. In particular, they compared people taking nitrogen-containing bisphosphonates, patients taking other osteoporosis medications, and people who received no such drug treatment. The figures of 16% and 24% are based on the results of these comparisons; the source does not describe them as evidence that the medication caused the observed difference.

The authors also estimated the potential effect in practical terms: according to their calculation, 48 patients would need to be treated for five years to potentially prevent one case of dementia. But this is not the result of a trial in which researchers assigned treatment in advance and tested its preventive effect. It is derived from observational data and depends on how closely the association found in the records reflects the effects of the drugs themselves. The estimate should therefore be viewed as a guide for future research, not as an established treatment standard.

What the results mean—and what they do not yet prove

The key limitation of the study is its observational nature. It shows that, among the patients studied, NBP use was associated with a lower risk of dementia, but it does not establish a causal relationship. This analysis cannot show that the medication itself caused the difference or promise protection for any individual. The researchers explicitly note that further studies are needed to determine the actual effectiveness of bisphosphonates in preventing or delaying cognitive decline.

The potential significance of the finding lies in evaluating existing medications, not in claiming that a new dementia treatment has emerged. Bisphosphonates are widely prescribed for osteoporosis and have a long track record of use in strengthening bones and reducing fracture risk. If future studies confirm a direct neuroprotective effect, this could be particularly significant for people who already need these medications for bone health. For now, however, the source describes a potential additional benefit, not an established indication for brain health.

Professor Chun-lung Cheung of HKUMed said the findings provide a basis for investigating a possible dual benefit: strengthening bones and potentially reducing the risk of dementia. This conclusion is consistent with a cautious interpretation of the data: the association identified is interesting, particularly given the stronger associations among women and people who had suffered a hip fracture, but it does not answer questions about the mechanism or direct effect. It remains unknown whether NBP’s preventive role will be confirmed in further studies; treatment should not be changed on the basis of this study alone.

Source: ScienceDaily